Invitrogen™ LILRC2 Polyclonal Antibody

Description

Reconstitute at 0.2 mg/mL in sterile PBS.

LILRC2, also known as Leukocyte Immunoglobulin-Like Receptor Subfamily C Member 2 (LILRC2), is a gene that encodes a member of the leukocyte immunoglobulin-like receptor (LILR) family. These receptors are primarily expressed on the surface of various immune cells, including B cells, dendritic cells, monocytes, and natural killer (NK) cells. LILRC2 functions as an inhibitory receptor, playing a critical role in the modulation of immune responses. By binding to specific ligands, such as major histocompatibility complex (MHC) class I molecules, LILRC2 can transmit inhibitory signals that dampen immune cell activation, thereby maintaining immune homeostasis and preventing excessive or inappropriate immune responses. This regulatory function is crucial for preventing autoimmunity and maintaining tolerance to self-antigens. Dysregulation or altered expression of LILRC2 has been associated with various immune-related conditions, including autoimmune diseases, chronic infections, and cancers. Understanding the specific roles and signaling mechanisms of LILRC2 is important for developing therapeutic strategies aimed at modulating immune responses, enhancing immune tolerance, and treating immune-mediated diseases. Research into LILRC2 provides valuable insights into the intricate balance of immune regulation and the potential for targeting inhibitory receptors in immunotherapy.